Hunan Warrant Pharmaceutical's Affiliate Receives Phase I Clinical Trial Report for ZG-002 Tablets

Stock News02-05 16:00

Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) announced that its equity-affiliated company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed a Phase I clinical trial for its independently developed ZG-002 tablets, conducted with the approval of the National Medical Products Administration. The clinical study report has recently been received. ZG-002 is a novel drug with a new chemical structure developed by Zhigen Pharmaceutical for the treatment of autoimmune diseases and is classified as a Category 1 new drug. It is currently intended for the treatment of moderate to severe plaque psoriasis. The Phase I trial primarily aimed to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 tablets in healthy adult subjects. Results indicated that the tablets demonstrated favorable safety and tolerability at the administered dose, frequency, and treatment duration, with clear and well-defined pharmacokinetic characteristics. The clinical data obtained from this study support further exploratory clinical research in patient populations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179769032?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179769032","market":"nz","top_or_hot":-1,"title":"Hunan Warrant Pharmaceutical's Affiliate Receives Phase I Clinical Trial Report for ZG-002 Tablets","media":"Stock News","content":"<p>Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) announced that its equity-affiliated company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed a Phase I clinical trial for its independently developed ZG-002 tablets, conducted with the approval of the National Medical Products Administration. The clinical study report has recently been received. ZG-002 is a novel drug with a new chemical structure developed by Zhigen Pharmaceutical for the treatment of autoimmune diseases and is classified as a Category 1 new drug. It is currently intended for the treatment of moderate to severe plaque psoriasis. The Phase I trial primarily aimed to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 tablets in healthy adult subjects. Results indicated that the tablets demonstrated favorable safety and tolerability at the administered dose, frequency, and treatment duration, with clear and well-defined pharmacokinetic characteristics. The clinical data obtained from this study support further exploratory clinical research in patient populations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hunan Warrant Pharmaceutical's Affiliate Receives Phase I Clinical Trial Report for ZG-002 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHunan Warrant Pharmaceutical's Affiliate Receives Phase I Clinical Trial Report for ZG-002 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-05 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) announced that its equity-affiliated company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed a Phase I clinical trial for its independently developed ZG-002 tablets, conducted with the approval of the National Medical Products Administration. The clinical study report has recently been received. ZG-002 is a novel drug with a new chemical structure developed by Zhigen Pharmaceutical for the treatment of autoimmune diseases and is classified as a Category 1 new drug. It is currently intended for the treatment of moderate to severe plaque psoriasis. The Phase I trial primarily aimed to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 tablets in healthy adult subjects. Results indicated that the tablets demonstrated favorable safety and tolerability at the administered dose, frequency, and treatment duration, with clear and well-defined pharmacokinetic characteristics. The clinical data obtained from this study support further exploratory clinical research in patient populations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZG","symbol_name":"Zillow Class A","start_time":0,"source_url":"","article_id":"1179769032","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179769032","pubTimestamp":1770278419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) announced that its equity-affiliated company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed a Phase I clinical trial for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688799":"华纳药厂","ZG":"Zillow Class A","BK4551":"寇图资本持仓","BK0239":"医药制造","BK4548":"巴美列捷福持仓","BK4079":"房地产服务"},"translate_title":"湖南权证药业关联公司收到ZG-002片I期临床试验报告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688799":1,"ZG":1},"content_text":"Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) announced that its equity-affiliated company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed a Phase I clinical trial for its independently developed ZG-002 tablets, conducted with the approval of the National Medical Products Administration. The clinical study report has recently been received. ZG-002 is a novel drug with a new chemical structure developed by Zhigen Pharmaceutical for the treatment of autoimmune diseases and is classified as a Category 1 new drug. It is currently intended for the treatment of moderate to severe plaque psoriasis. The Phase I trial primarily aimed to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 tablets in healthy adult subjects. Results indicated that the tablets demonstrated favorable safety and tolerability at the administered dose, frequency, and treatment duration, with clear and well-defined pharmacokinetic characteristics. The clinical data obtained from this study support further exploratory clinical research in patient populations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179769032","isCrawlerRequest":true}